Do analysts prefer RDY or ATAI?

Atai Beckley has a consensus target price of $10.56, suggesting a potential upside of 43.04%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts plainly believe Atai Beckley is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Atai Beckley 1 Sell rating(s) 14 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.06

Which has preferable earnings and valuation, ATAI or LQDA?

Liquidia has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 669.18 -$660.05M -$2.18 N/A Liquidia $450.91M 13.95 -$68.92M $1.37 51.29

Is ATAI or LQDA more profitable?

Liquidia has a net margin of 30.74% compared to Atai Beckley's net margin of -14,938.36%. Liquidia's return on equity of 149.65% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Liquidia 30.74% 149.65% 36.30%

Which has stronger earnings and valuation, ATAI or LNTH?

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 669.18 -$660.05M -$2.18 N/A Lantheus $1.54B 4.27 $233.56M $4.14 24.35

Is ATAI or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Atai Beckley's net margin of -14,938.36%. Lantheus' return on equity of 28.10% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Lantheus 17.69% 28.10% 14.35%

Is ATAI or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Belite Bio's return on equity of -11.84% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Belite Bio N/A -11.84% -11.62%

Atai Beckley (ATAI) Competitors

$7.38 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.38 0.00 (-0.05%)

As of 04:29 PM Eastern

Compare

ATAI vs. RDY, CRNX, LQDA, LNTH, and BLTE

Should you buy Atai Beckley stock or one of its competitors? Atai Beckley's main competitors and comparable companies include Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Liquidia (LQDA), Lantheus (LNTH), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Dr. Reddy's Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

In the previous week, Atai Beckley had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Atai Beckley and 2 mentions for Dr. Reddy's Laboratories. Atai Beckley's average media sentiment score of 0.67 beat Dr. Reddy's Laboratories' score of -0.73 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Negative
Atai Beckley	Positive

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 19.8% of Atai Beckley shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Atai Beckley's net margin of -14,938.36%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Atai Beckley has a consensus target price of $10.56, suggesting a potential upside of 43.04%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts plainly believe Atai Beckley is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Dr. Reddy's Laboratories has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.85	$456M	$0.44	27.76
Atai Beckley	$4.09M	669.18	-$660.05M	-$2.18	N/A

Summary

Atai Beckley beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Atai Beckley (NASDAQ:ATAI) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Crinetics Pharmaceuticals has higher revenue and earnings than Atai Beckley. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$42.16M	213.31	-$465.32M	-$5.04	N/A
Atai Beckley	$4.09M	669.18	-$660.05M	-$2.18	N/A

Crinetics Pharmaceuticals has a net margin of -1,189.88% compared to Atai Beckley's net margin of -14,938.36%. Crinetics Pharmaceuticals' return on equity of -44.22% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Atai Beckley had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 6 mentions for Atai Beckley and 4 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.26 beat Atai Beckley's score of 0.67 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Positive
Atai Beckley	Positive

Crinetics Pharmaceuticals has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

Crinetics Pharmaceuticals currently has a consensus price target of $81.00, indicating a potential downside of 4.46%. Atai Beckley has a consensus price target of $10.56, indicating a potential upside of 43.04%. Given Atai Beckley's higher possible upside, analysts plainly believe Atai Beckley is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Summary

Crinetics Pharmaceuticals beats Atai Beckley on 9 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Liquidia?

Atai Beckley (NASDAQ:ATAI) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Atai Beckley presently has a consensus target price of $10.56, indicating a potential upside of 43.04%. Liquidia has a consensus target price of $98.08, indicating a potential upside of 39.58%. Given Atai Beckley's higher possible upside, equities research analysts plainly believe Atai Beckley is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Liquidia has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	669.18	-$660.05M	-$2.18	N/A
Liquidia	$450.91M	13.95	-$68.92M	$1.37	51.29

Atai Beckley has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Atai Beckley's net margin of -14,938.36%. Liquidia's return on equity of 149.65% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Liquidia	30.74%	149.65%	36.30%

In the previous week, Liquidia had 9 more articles in the media than Atai Beckley. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.67 beat Liquidia's score of 0.53 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Positive
Liquidia	Positive

Summary

Liquidia beats Atai Beckley on 12 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Lantheus?

Atai Beckley (NASDAQ:ATAI) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

In the previous week, Lantheus had 3 more articles in the media than Atai Beckley. MarketBeat recorded 9 mentions for Lantheus and 6 mentions for Atai Beckley. Lantheus' average media sentiment score of 1.28 beat Atai Beckley's score of 0.67 indicating that Lantheus is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Positive
Lantheus	Positive

Atai Beckley has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Atai Beckley presently has a consensus price target of $10.56, indicating a potential upside of 43.04%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.25%. Given Atai Beckley's higher probable upside, analysts clearly believe Atai Beckley is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has a net margin of 17.69% compared to Atai Beckley's net margin of -14,938.36%. Lantheus' return on equity of 28.10% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Lantheus	17.69%	28.10%	14.35%

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	669.18	-$660.05M	-$2.18	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.35

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lantheus beats Atai Beckley on 12 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Belite Bio?

Atai Beckley (NASDAQ:ATAI) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Belite Bio's return on equity of -11.84% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Belite Bio	N/A	-11.84%	-11.62%

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 19.8% of Atai Beckley shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atai Beckley has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market.

Belite Bio has lower revenue, but higher earnings than Atai Beckley. Belite Bio is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	669.18	-$660.05M	-$2.18	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Atai Beckley had 2 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Atai Beckley and 4 mentions for Belite Bio. Atai Beckley's average media sentiment score of 0.67 beat Belite Bio's score of -0.75 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Positive
Belite Bio	Negative

Atai Beckley presently has a consensus price target of $10.56, indicating a potential upside of 43.04%. Belite Bio has a consensus price target of $205.80, indicating a potential upside of 29.54%. Given Atai Beckley's higher probable upside, equities research analysts clearly believe Atai Beckley is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Atai Beckley beats Belite Bio on 10 of the 16 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.74B	$12.44B	$7.30B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	-3.39	780.41	271.39	24.11
Price / Sales	669.18	788.61	604.56	77.78
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	10.70	10.42	11.18	6.40
Net Income	-$660.05M	$2.79B	$3.46B	$348.28M
7 Day Performance	1.93%	2.28%	1.97%	0.95%
1 Month Performance	2.79%	4.73%	7.30%	5.15%
1 Year Performance	61.49%	7.09%	24.74%	16.18%

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	3.3991 of 5 stars	$7.38 flat	$10.56 +43.0%	+61.5%	$2.74B	$4.09M	N/A	80	Analyst Revision
RDY Dr. Reddy's Laboratories	1.8255 of 5 stars	$12.15 -1.0%	N/A	-16.0%	$10.24B	$3.58B	27.61	27,527
CRNX Crinetics Pharmaceuticals	1.9495 of 5 stars	$84.75 +0.1%	$81.00 -4.4%	+173.9%	$8.98B	$7.70M	N/A	210	Positive News
LQDA Liquidia	4.2991 of 5 stars	$77.70 +4.4%	$98.08 +26.2%	+155.7%	$6.66B	$158.32M	56.72	50	Insider Trade
LNTH Lantheus	3.3527 of 5 stars	$100.91 0.0%	$108.11 +7.1%	+71.7%	$6.59B	$1.54B	24.37	1,193	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. RDY, CRNX, LQDA, LNTH, and BLTE

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Summary

How does Atai Beckley compare to Liquidia?

Summary

How does Atai Beckley compare to Lantheus?

Summary

How does Atai Beckley compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. RDY, CRNX, LQDA, LNTH, and BLTE

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Which has more volatility & risk, RDY or ATAI?

Does the media prefer RDY or ATAI?

Do insiders and institutionals have more ownership in RDY or ATAI?

Is RDY or ATAI more profitable?

Do analysts prefer RDY or ATAI?

Which has better valuation and earnings, RDY or ATAI?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Which has stronger valuation and earnings, CRNX or ATAI?

Is CRNX or ATAI more profitable?

Do institutionals and insiders believe in CRNX or ATAI?

Does the media refer more to CRNX or ATAI?

Which has more volatility and risk, CRNX or ATAI?

Do analysts rate CRNX or ATAI?

Summary

How does Atai Beckley compare to Liquidia?

Do institutionals and insiders believe in ATAI or LQDA?

Do analysts rate ATAI or LQDA?

Which has preferable earnings and valuation, ATAI or LQDA?

Which has more volatility and risk, ATAI or LQDA?

Is ATAI or LQDA more profitable?

Does the media prefer ATAI or LQDA?

Summary

How does Atai Beckley compare to Lantheus?

Does the media favor ATAI or LNTH?

Which has more volatility and risk, ATAI or LNTH?

Do analysts rate ATAI or LNTH?

Is ATAI or LNTH more profitable?

Which has stronger earnings and valuation, ATAI or LNTH?

Do institutionals and insiders have more ownership in ATAI or LNTH?

Summary

How does Atai Beckley compare to Belite Bio?

Is ATAI or BLTE more profitable?

Do insiders and institutionals have more ownership in ATAI or BLTE?

Which has more volatility and risk, ATAI or BLTE?

Which has stronger valuation & earnings, ATAI or BLTE?

Does the media refer more to ATAI or BLTE?

Do analysts recommend ATAI or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools